Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Cancer|July 24, 2009
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trialBruno Vincenzi, Daniele Santini, Antonio Russo, et al.
Transfusion|November 5, 2015
Albumin versus solvent/detergent-treated pooled plasma as replacement fluid for long-term plasma exchange therapy in a patient with primary hypertriglyceridemia and recurrent hyperlipidemic pancreatitisDanilo Di Bona, Angelo B Cefalù, Elisabetta Scirè, et al.
Critical Reviews in Oncology/Hematology|September 18, 2013
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspectsGiuseppe Bronte, Christian Rolfo, Elisa Giovannetti, et al.
Therapeutic Advances in Medical Oncology|October 14, 2021
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analysesValerio Gristina, Antonio Galvano, Luisa Castellana, et al.
Immunology|October 16, 2019
The immunoglobulin γ marker 17 allotype and KIR/HLA genes prevent the development of chronic hepatitis B in humansDanilo Di Bona, Janardan P Pandey, Anna Aiello, et al.
Critical Reviews in Oncology/Hematology|April 30, 2015
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysisGiuseppe Bronte, Christian Rolfo, Francesco Passiglia, et al.
Therapeutic Advances in Medical Oncology|April 26, 2019
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patientsFrancesco Passiglia, Antonio Galvano, Marta Castiglia, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|June 20, 2007
Prevalence of tobacco use in Eritrea: results from a noncommunicable disease risk factor surveyJacob Mufunda, Amanuel Debesay, Asgedom Mosazghi, et al.
Critical Reviews in Oncology/Hematology|August 5, 2019
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trialsDaniele Santini, Antonio Galvano, Francesco Pantano, et al.
The Oncologist|January 7, 2010
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenibBruno Vincenzi, Daniele Santini, Antonio Russo, et al.
Pageof 7